Back to top
more

Caribou Biosciences (CRBU)

(Delayed Data from NSDQ)

$2.68 USD

2.68
2,467,946

-0.10 (-3.60%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $2.68 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 13.64% and 39.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 6.67% and 4.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 285.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 321.5% in Caribou Biosciences, Inc. (CRBU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of 285.45% and 168.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.

Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut

by Zacks Equity Research

Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 2.04% and 8.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

by Zacks Equity Research

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.

CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.

CRISPR (CRSP) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.

Geron (GERN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -12.50% and 79.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

Incyte (INCY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.

Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.